– November 1, 2003
November 1, 2003
View Issues
-
Palonosetron Improves Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy
The prevention of acute chemotherapy-induced nausea and vomiting (CINV) has improved dramatically in the past decade. -
Prophylactic G-CSF for Elderly Lymphoma Patients: Negative Findings
In a trial of elderly patients with non-Hodgkins lymphoma, the prophylactic use of granulocyte colony-stimulating factor did not improve clinical outcomes, including hospitalization rate and survival. -
Extrapleural Pneumonectomy Permits More Effective Radiotherapy Dose Delivery for Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is an uncommon tumor that carries a dismal prognosis. Its incidence is rising and is expected to continue climbing as more patients reach the end of the 35-40-year lag period between asbestos exposure and tumor development. -
CML Treatment in the Elderly
In a 4-year review of chronic myelogenous treatment responses with imatinib mesylate at a single institution, older patients were found to have comparable outcomes to younger patients. -
12 vs 3 Months of Maintenance Paclitaxel in Patients with Advanced Ovarian Cancer after Platinum and Paclitaxel-Based Chemotherapy
Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of progression-free survival. -
Pharmacology Watch: Generic Paxil Scheduled to Hit Market this Fall
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.